Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CSL324 lung endotoxin challenge study
NCT05653713Phase 1Completed
- Sponsor
- CSL Limited
- Start
- Dec 2022
- Primary completion
- Jul 2023
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in chronic obstructive pulmonary disease (COPD) comparing CSL324 with Placebo (2 arms). Primary endpoint: Percent reduction in mean absolute neutrophil cell counts in bronchoalveolar lavage fluid (BALF). Started Dec 2022; status: completed.
02
Drugs
anumigilimab
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT05653713.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05653713.